News

Aspen’s products portfolio recorded revenue of A$106m and a direct contribution to profit before tax of A$26m for the year ended 30 June 2014. To be operated under

This is the company’s third product to receive this QIDP status after WCK 771 and WCK 2349 last year further strengthening its new drug discovery program. QIDP status

Primary immunodeficiencies are a group of disorders in which part of the body’s immune system is missing or does not function properly. The company is advancing the 20%

Under the deal, Eureka will apply its proprietary human sequence antibody libraries and its technology platform to discover antibodies recognizing intracellular proteins, which represent about 90% of cancer-specific

Highlights The agreement includes the creation of an incubator focused on potential treatments for major diseases such as breast cancer and lung fibrosis using the modulation of RHAMM.

ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma

Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company – includes Italy, China and eight countries in Southeast Asia. In addition to

Neurodegenerative diseases, such as Alzheimer’s disease (AD), Hutchinson’s Disease, Parkinson’s disease, Kuru, Creutzfeldt-Jakob disease and other spongiform encephalopathies remain major health problems. Currently there are very limited means

NPC-1C targets a unique member of the MUC family that is specific to colorectal cancer with little reactivity to normal cells. Encouraging overall survival (OS) data was observed